US Liver Cancer Drugs Market Report 2022 to 2030

US Liver Cancer Drugs Market Analysis

$ 3999

US liver cancer drugs market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The rising incidence of liver cancer and the accessibility of novel medications are the two main drivers of market expansion over the forecast period. In the upcoming years, market expansion is anticipated to be fueled by increased investments in the research & development industry and the discovery of novel medicines. The major key players in this market are Bayer HealthCare Pharmaceuticals Inc. (Germany), Bristol-Myers & Squibb Company (US), Pfizer Inc. (US), Exelixis, Inc. (US), Merck Sharp & Dohme Corp. (US), Eisai Inc. (Japan), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland).

ID: IN10USPH325 CATEGORY: Pharmaceuticals GEOGRAPHY: US AUTHOR: Riddhi Solanki

Buy Now

US Liver Cancer Drugs Market Analysis Summary

US Liver Cancer Drugs Market is valued at around $906.8 Mn in 2022 and is projected to reach $2343.2 Mn by 2030, exhibiting a CAGR of 12.6% during the forecast period 2023-2030.

Liver cancer is a type of cancer that develops in the cells of the liver. It is a chronic, life-threatening illness that develops over time and begins in the cells of the liver. Liver cancer can take many different forms, including primary hepatic cancer, which arises in hepatocyte cells, and metastatic cancer, which travels to the liver from another part of the body. Because the majority of systemic drugs are ineffectual in the treatment of liver cancer, research and development are mostly concentrated on the molecular processes involved in hepatocarcinogenesis. Future entry into the liver cancer treatment market of a large range of novel drugs with several first-in-class developments in each major target family will certainly increase the spectrum of potential patient benefits. In development and licencing agreements, small compounds made up the largest group of product candidates, followed by monoclonal antibodies. Many candidates in the pipeline aim to fix broken signalling pathway elements. Oncolytic viruses and RNA interference (RNAi) technology are two cutting-edge therapy modalities that have garnered a lot of interest in the industry. The rising incidence of liver cancer and the accessibility of novel medications are the two main drivers of market expansion over the forecast period. In the upcoming years, market expansion is anticipated to be fueled by increased investments in the research & development industry and the discovery of novel medicines. The major key players in this market are Bayer HealthCare Pharmaceuticals Inc. (Germany), Bristol-Myers & Squibb Company (US), Pfizer Inc. (US), Exelixis, Inc. (US), Merck Sharp & Dohme Corp. (US), Eisai Inc. (Japan), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland).

Market Dynamics

Market Growth Drivers

Globally, liver cancer is becoming more common and has surpassed cardiovascular illnesses as the second leading cause of death. Environmental factors, alcohol usage, smoking, and increasing urbanisation are the main contributors to its prevalence. For instance, according to the World Cancer Research Fund, there were over 840 000 new instances of liver cancer last year. As a result, it is anticipated that rising prevalence and need for efficient drugs will fuel market growth. Every year, the speed of cancer research and development to provide cutting-edge patient care quickens. The number of liver cancer therapy options under development has increased as a result of innovative investigations leading to combination therapies involving novel or already licenced pharmacological agents. Additionally, the large funding provided for R&D by domestic and foreign healthcare organisations is likely to have an impact on the market potential for liver cancer. When coupled with customers' growing desire for new biosimilar products, this is anticipated to hasten market expansion.

Market Restraints

When high doses of the drugs are used to treat cancer cells, the tumour cells are eliminated and the healthy body cells suffer more severe harm. As a result, a lot of people encounter a variety of negative side effects, such as gastrointestinal problems, hair loss, tiredness, skin problems, etc. As a result, the development of the global market for medicines to treat liver cancer is being hampered by significant side effects associated with anticancer drugs. The strict guidelines set forth by regulatory organisations for clinical research are another factor limiting industry growth.

Competitive Landscape

Key Players

Bayer HealthCare Pharmaceuticals Inc. (Germany)
Bristol-Myers & Squibb Company (US)
Pfizer Inc. (US)
Exelixis, Inc. (US)
Merck Sharp & Dohme Corp. (US)
Eisai Inc. (Japan)
Eli Lilly and Company (US)
F. Hoffmann-La Roche Ltd (Switzerland)

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

US Liver Cancer Drugs Market Segmentation

By Therapeutic Class

Targeted Therapy
Immunotherapy
Chemotherapy
Radiation Therapy

By Type

Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types

By End Users

Hospitals
Specialty Clinics
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.